These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 35543545)

  • 21. Clinical manifestations and analytical reports for MDPHP acute intoxication cases.
    Arillotta D; Totti A; Dimitrova A; Croce EB; Di Milia MG; Gambassi F; Gualco B; Pieraccini G; Mannaioni G; Vaiano F
    J Pharm Biomed Anal; 2024 Apr; 241():115974. PubMed ID: 38277706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Different Psychoactive Substances on Serum Biochemical Parameters.
    Sanli DB; Bilici R; Suner O; Citak S; Kartkaya K; Mutlu FS
    Int J High Risk Behav Addict; 2015 Jun; 4(2):e22702. PubMed ID: 26405680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decriminalisation and smart regulation of psychoactive substances: a modern alternative to prohibition.
    Mravčík V
    Cas Lek Cesk; 2023; 162(6):231-237. PubMed ID: 38981723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental versus theoretical log D
    Manchester KR; Maskell PD; Waters L
    Drug Test Anal; 2018 Mar; ():. PubMed ID: 29582576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Editorial: Old and new psychoactive substances: Pharmacology and potential applications.
    Mayer FP; Luethi D; Areal LB; Sitte HH
    Front Psychiatry; 2022; 13():1087005. PubMed ID: 36684007
    [No Abstract]   [Full Text] [Related]  

  • 26. The emergence of nitazenes on the Irish heroin market and national preparation for possible future outbreaks.
    Killeen N; Lakes R; Webster M; Killoran S; McNamara S; Kavanagh P; Eagleton M; McCormack S; Micheau E; Moughty A; O'Donnell C; O'Reilly M; Doyle G; O'Rourke S; Downing S; Flynn C; Keenan E
    Addiction; 2024 May; ():. PubMed ID: 38720174
    [No Abstract]   [Full Text] [Related]  

  • 27. Vasospasm due to ingestion of a combination of psychoactive substances: A case study.
    Torres-Patiño IC; Fernandes-Pineda M; Ayala-Zapata S
    Med Clin (Barc); 2024 Apr; ():. PubMed ID: 38688738
    [No Abstract]   [Full Text] [Related]  

  • 28. Withdrawn: Predicting the lethal toxicity of psychoactive substances.
    King LA
    Drug Test Anal; 2022 Jun; 14(6):1170. PubMed ID: 33238076
    [No Abstract]   [Full Text] [Related]  

  • 29. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
    Gray R; Bressington D; Hughes E; Ivanecka A
    J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature.
    Chiappini S; Mosca A; Miuli A; Santovito MC; Orsolini L; Corkery JM; Guirguis A; Pettorruso M; Martinotti G; Di Giannantonio M; Schifano F
    Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34204131
    [No Abstract]   [Full Text] [Related]  

  • 31. Analytically confirmed presence of psychoactive substances, especially new psychoactive substances in a group of patients hospitalized with mental and behavioural disorders due to the use of psychoactive substances diagnosis.
    Engelgardt P; Krzyżanowski M; Piotrowski P; Borkowska-Sztachańska M; Wasilewska A
    Int J Occup Med Environ Health; 2022 Aug; 35(4):485-495. PubMed ID: 35543545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of psychiatric inpatients diagnosed with mental and behavioral disorders caused by psychoactive substances (F11-19 block), with a focus on NPS and psychiatric co-morbidities.
    Engelgardt P; Krzyżanowski M; Piotrowski P; Borkowska-Sztachańska M; Wasilewska A; Kowalkowski T
    Int J Occup Med Environ Health; 2020 Mar; 33(2):125-136. PubMed ID: 31942874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of synthetic cannabinoids that were seized, consumed, or associated with deaths in Kuwait in 2018 using GC-MS and LC-MS-MS analysis.
    Al-Matrouk A; Alqallaf M; AlShemmeri A; BoJbarah H
    Forensic Sci Int; 2019 Oct; 303():109960. PubMed ID: 31550599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive Monitoring of Psychoactive Substances in Psychiatric Patients Using Liquid Chromatography-High-Resolution Mass Spectrometry: A Key Tool for Treatment Planning and Understanding Consumption Patterns in Rome, Italy.
    La Maida N; Di Giorgi A; Pichini S; Pellegrini M; Di Trana A; Elmo MG; Polselli GM; Casella P; Di Stefano A; Ducci G
    Ther Drug Monit; 2024 Apr; 46(2):203-209. PubMed ID: 38018870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines, and cannabinoids in human whole blood by liquid chromatography-tandem mass spectrometry - A New Zealand perspective of use in 2018.
    Ong RS; Kappatos DC; Russell SGG; Poulsen HA; Banister SD; Gerona RR; Glass M; Johnson CS; McCarthy MJ
    Drug Test Anal; 2020 Feb; 12(2):195-214. PubMed ID: 31595682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I metabolism of the highly potent synthetic cannabinoid MDMB-CHMICA and detection in human urine samples.
    Franz F; Angerer V; Moosmann B; Auwärter V
    Drug Test Anal; 2017 May; 9(5):744-753. PubMed ID: 27504870
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.